Skip to main content

Merck & Co: Keytruda Headed for Extended Dominance in Cancer Market

Merck & Co. Inc. (NYSE:MRK) announced today that Keytruda—its cancer drug—has been granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL). The announcement marks the fourth breakthrough therapy designation for the first-ever anti-PD-1 therapy to be approved in the US.

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino